Thromb Haemost 2002; 87(01): 7-12
DOI: 10.1055/s-0037-1612936
In Focus
Schattauer GmbH

Risk of Venous Thromboembolism Recurrence: High Negative Predictive Value of D-dimer Performed after Oral Anticoagulation Is Stopped

Gualtiero Palareti
1   Department of Angiology, Unità Ricerca Clinica sulla Trombofilia “M. Golinelli”, University Hospital S. Orsola-Malpighi, Bologna, Italy
,
Cristina Legnani
1   Department of Angiology, Unità Ricerca Clinica sulla Trombofilia “M. Golinelli”, University Hospital S. Orsola-Malpighi, Bologna, Italy
,
Benilde Cosmi
1   Department of Angiology, Unità Ricerca Clinica sulla Trombofilia “M. Golinelli”, University Hospital S. Orsola-Malpighi, Bologna, Italy
,
Giuliana Guazzaloca
1   Department of Angiology, Unità Ricerca Clinica sulla Trombofilia “M. Golinelli”, University Hospital S. Orsola-Malpighi, Bologna, Italy
,
Claudia Pancani
1   Department of Angiology, Unità Ricerca Clinica sulla Trombofilia “M. Golinelli”, University Hospital S. Orsola-Malpighi, Bologna, Italy
,
Sergio Coccheri
1   Department of Angiology, Unità Ricerca Clinica sulla Trombofilia “M. Golinelli”, University Hospital S. Orsola-Malpighi, Bologna, Italy
› Author Affiliations
Further Information

Publication History

Received 30 April 2001

Accepted 10 September 2001

Publication Date:
13 December 2017 (online)

Summary

In some patients with previous venous thromboembolism (VTE) D-dimer levels (D-Dimer) tend to increase after oral anticoagulant therapy (OAT) is stopped. The aim of our study was to evaluate the predictive value of D-Dimer for the risk of VTE recurrence after OAT withdrawal. After a first episode of deep vein thrombosis (DVT) of the lower limbs and/or pulmonary embolism (PE), 396 patients (median age 67 years, 198 males) were followed from the day of OAT discontinuation for 21 months. D-dimer was measured on the day of OAT withdrawal (T1), 3-4 weeks (T2) and 3 months (+/− 10 days, T3) thereafter. The main outcome events of the study were: objectively documented recurrent DVT and/or PE. D-dimer was found to be increased in 15.5%, 40.3% and 46.2% of the patients at T1, T2 and T3, respectively. In 199 (50.2%) patients, D-dimer levels were elevated in at least one measurement. During a follow-up of 628.4 years, 40 recurrences were recorded (10.1% of patients; 6.4% patient-years of follow-up). D-dimer was increased in at least one measurement in 28 of these cases, but remained normal in 11 subjects (three of whom had recurrent events triggered by circumstantial factors, three with malignancyassociated factors) (in one subject D-dimer was not measured). The negative predictive value (NPV) of D-dimer was 95.6% (95% CI 91.6-98.1) at T3 and was even higher (96.7%; 95% CI 92.9-98.8) after exclusion of the six recurrences due to circumstantial factors. Only five idiopathic recurrences occurred in the 186 patients with consistently normal D-dimer. In conclusion, D-dimer has a high NPV for VTE recurrence when performed after OAT discontinuation.

 
  • References

  • 1 Hirsh J, Kearon C, Ginsberg J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med 1997; 157: 2174-7.
  • 2 Hull R, Delmore T, Genton E. et al. Warfarin sodium versus low dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-8.
  • 3 Hyers TM, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176S-193S.
  • 4 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-6.
  • 5 Levine MN, Hirsh J, Gent M. et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
  • 6 Schulman S, Rhedin AS, Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
  • 7 Schulman S, Granqvist S, Holmstrom M. et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-8.
  • 8 Kearon C, Gent M, Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
  • 9 Perrier A, Desmarais S, Miron MJ. et al. Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet 1999; 353: 190-5.
  • 10 Bounameaux H, Perrier A. Rapid diagnosis of deep vein thrombosis in symptomatic patients: a comparison between four different diagnostic strategies. Thromb Haemost 1999; 82: 1360-1.
  • 11 Palareti G, Legnani C, Guazzaloca G. et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants - a prospective study. Thromb Haemost 1994; 72: 222-6.
  • 12 Sie P, Cadroy Y, Elias A, Boccalon H, Boneu B. D-dimer levels in patients with long-term antecedents of deep venous thrombosis. Thromb Haemost 1994; 72: 161-2.
  • 13 Kevorkian JP, Halimi C, Segrestaa JM, Drouet L, Soria C. Monitoring of patients with deep-vein thrombosis during and after anticoagulation with D-dimer. Lancet 1998; 351: 571-2.
  • 14 Lowe GDO, Haverkate F, Thompson SG. et al. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT study. Thromb Haemost 1999; 81: 879-6.
  • 15 Prandoni P, Lensing AWA, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
  • 16 Eekhoff EMW, Rosendaal FR, Vandenbroucke JP. Minor events and the risk of deep venous thrombosis. Thromb Haemost 2000; 83: 408-11.